Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure (NRII)
Sponsor: University of Washington
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Purpose
To address a key gap in current knowledge by assessing the mechanisms through which raising blood and myocardial NAD+ levels in humans mediates changes in mitochondrial function, protein and epigenetic modifications, as well as inflammation.
Study Design
Randomized, double-blind, placebo controlled, parallel assignment
Dose
Dose escalation from 250mg twice daily (500mg NR/day) to 1000mg twice daily (2000mg NR/day)
Length of Intervention
4-14 days
Intrinsic Capacity
Vitality
Status
Not Yet Recruiting
Condition or Disease
Heart Failure
Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.